TABLE 2

Summary of EGP, hepatic glycogenolysis, and gluconeogenesis in 7 type 2 diabetic and 9 nondiabetic volunteers

Type 2 diabetic subjects
Control subjects
Absolute rate (μmol · kg−1 · min−1)Fraction of EGP (%)Absolute rate (μmol · kg−1 · min−1)Fraction of EGP (%)
EGP16.3 ± 1.2*10011.2 ± 0.4100
Glycogenolysis2.3 ± 0.2*15 ± 2*3.9 ± 0.435 ± 3
GNG (13C-MRS)14 ± 1.3*85 ± 2*7.3 ± 0.465 ± 3
GNG (2H-NMR)75 ± 2*63 ± 3
GNG (HMT)63 ± 3*51 ± 3
  • Data are means ± SEM. Comparison of estimates of gluconeogenesis (GNG) as calculated from 5:2 ratios in plasma glucose measured with in vitro 2H-NMR spectroscopy, from HMT and from the difference between EGP and hepatic glycogenolysis measured with in vivo 13C-MRS.

  • *

    * P < 0.01 vs. control subjects

  • P < 0.005 vs. HMT.